Drug
D1059 | pirarubicin
L
L01DB08 Pirarubicin
[L01DB] Anthracyclines and related substances
[L01D] CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
[L01] ANTINEOPLASTIC AGENTS
[L] Antineoplastic and immunomodulating agents
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 0.60±0.46 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.69 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.03±0.00 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| (8S)-10-((2R,4S,5S,6S)-4-amino-6-methyl-5-((S)-tetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione | (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-6-methyl-5-(((S)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; | 15207-EP2272827A1 |
| 15207-EP2275420A1 | 15207-EP2295055A2 | 15207-EP2295416A2 |
| 15207-EP2295426A1 | 15207-EP2295427A1 | 15207-EP2298748A2 |
| 15207-EP2298764A1 | 15207-EP2298765A1 | 15207-EP2298768A1 |
| 15207-EP2298778A1 | 15207-EP2305642A2 | 15207-EP2311453A1 |
| 15207-EP2311808A1 | 15207-EP2311829A1 | 15207-EP2316832A1 |
| 15207-EP2316833A1 | 496P414 | 72496-41-4 |
| AKOS015895621 | AOB5649 | C32H37NO12 |
| CHEBI:32011 | CHEMBL1398373 | D01885 |
| EX-A494 | K234 | KMSKQZKKOZQFFG-HSUXVGOQSA-N |
| MFCD00869742 | NCGC00167982-01 | NCGC00167982-02 |
| Pirarubicin (JP17/INN) | Pirarubicin, Antibiotic for Culture Media Use Only | Q-201589 |
| SCHEMBL15472856 | THP-doxorubicin | Theprubicin |
| ZINC3913909 | pirarubicin |